Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI)

Six economic evaluations (two cost-effectiveness analyses; two cost-utility analyses; two combined cost-effectiveness and cost utility analyses) were included. All studies were of good quality and adopted the perspective of the healthcare system/payer; accordingly, only direct medical costs were considered. Of particular concern were the use of not recommended genes (i.e. BRAF, PTEN, ERBB2) as predictive biomarkers for response to anti-EGFR therapy, the lack of consideration of NRAS mutation status and of key parameters related to genetic tests and biological agents. Two studies were funded by Roche, a leading provider of genetic tests, and the source of funding was not declared in one study. Four studies presented testing strategies with a favorable ICER under the National Institute for Clinical Excellence (£20,000-30,000/QALY) and the US ($50,000-100,000/ QALY) thresholds.